Cardiome Reports Commercialization Deal for Brianavess with LifePharma in Cyprus, No Terms Disclosed
September 24, 2013 at 11:01 AM EDT
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that its subsidiary, Cardiome Development AG, has entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and distribute BRINAVESS™ (vernakalant intravenous) exclusively in Cyprus. Under the terms of the agreement, LifePharma has agreed to specific annual commercial goals for